Stock SANA SANA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
10.44 USD +6.75% Intraday chart for Sana Biotechnology, Inc. +19.72% +155.88%
04-18 Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development CI
04-09 Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024. CI

Business Summary

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Number of employees: 328

Managers

Managers TitleAgeSince
Steven Harr FOU
 Founder 53 12/07/18
Nathan Hardy DFI
 Director of Finance/CFO 48 31/08/18
Gary Meininger CTO
 Chief Tech/Sci/R&D Officer - 09/04/23
Shanna Peek COO
 Chief Operating Officer - 30/06/19
Edward Rebar CTO
 Chief Tech/Sci/R&D Officer 56 29/02/20
Richard Mulligan CTO
 Chief Tech/Sci/R&D Officer 69 31/10/18
Ke Liu LAW
 General Counsel - 05/01/21
Sonja Schrepfer PRN
 Corporate Officer/Principal 49 31/01/19
Steven Goldman PRN
 Corporate Officer/Principal 66 30/09/20
Terry Fry PRN
 Corporate Officer/Principal 57 31/07/20

Members of the board

Members of the board TitleAgeSince
Maggie Wilderotter BRD
 Director/Board Member 69 30/04/20
Patrick Yang BRD
 Director/Board Member 75 30/09/18
Robert Nelsen FOU
 Founder 60 12/07/18
Douglas Cole BRD
 Director/Board Member 63 31/03/20
Steven Harr FOU
 Founder 53 12/07/18
Josh Bilenker BRD
 Director/Board Member 52 07/01/21
Richard Mulligan CTO
 Chief Tech/Sci/R&D Officer 69 31/10/18
Hans Bishop FOU
 Founder 59 12/07/18
Michelle Seitz BRD
 Director/Board Member 59 30/11/20
Alise Reicin BRD
 Director/Board Member 63 30/11/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 221,323,414 201,274,718 ( 90.94 %) 0 90.94 %

Shareholders

NameEquities%Valuation
ARCH Venture Partners LLC
20.80 %
45,860,681 20.80 % 459 M $
Flagship Pioneering
11.34 %
25,001,856 11.34 % 250 M $
Baillie Gifford & Co.
4.834 %
10,656,279 4.834 % 107 M $
Baillie Gifford & Co.
4.700 %
10,360,620 4.700 % 104 M $
Canada Pension Plan Investment Board
4.616 %
10,175,000 4.616 % 102 M $
Vanguard Fiduciary Trust Co.
4.444 %
9,797,084 4.444 % 98 M $
Fidelity Management & Research Co. LLC
4.138 %
9,122,454 4.138 % 91 M $
Steven Harr
4.017 %
8,856,250 4.017 % 89 M $
BlackRock Advisors LLC
3.645 %
8,035,257 3.645 % 80 M $
STATE STREET CORPORATION
2.680 %
5,908,687 2.680 % 59 M $

Company contact information

Sana Biotechnology, Inc.

188 East Blaine Street Suite 400

98102, Seattle

+

http://www.sana.com
address Sana Biotechnology, Inc.(SANA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.44 USD
Average target price
11.5 USD
Spread / Average Target
+10.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SANA BIOTECHNOLOGY, INC. Stock Sana Biotechnology, Inc.
+155.88% 2.31B
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SANA Stock
  4. Company Sana Biotechnology, Inc.